Ocular Stem Cell Studies

Jeffrey N. Weiss, M.D., is the former Chief of Retinal Surgery at the Joslin Diabetes Center in Boston, Faculty of Harvard Medical School, and Visiting Scientist at the Massachusetts Institute of Technology.

Dr. Weiss is the author of more than 100 publications, including 20 books, holds more than 20 U.S. and foreign patents and has been a Reviewer for multiple scholarly journals. He has served as a Visiting Professor, performed surgery, and lectured both nationally and internationally. Dr. Weiss is also the founder of two companies, Ocular Research Associates Inc., and Micron Ophthalmic, Inc., which have manufactured and sold Dr. Weiss' inventions worldwide.

Dr. Weiss was the first to invent the equipment and develop the technique to safely perform retinal vessel cannulation. This surgery remains the only option for patients with severe stroke in the eye. He was also the first to report the use of hyperbaric oxygen treatment to successfully treat dry age-related macular degeneration and longer standing central retinal artery occlusions.

Dr. Weiss performed the first retinal stem cell surgery in 2010, and is the Principal Investigator of The Stem Cell Ophthalmology Treatment Studies I/II, the largest retinal and optic nerve stem cell studies in the world, and The Neurologic Stem Cell Treatment Study. The studies are Institutional Review Board (IRB) approved, registered with NIH, and listed on ClinicalTrials.gov.

Section 1: Active/Recruiting Studies.- Section 1, Part 1: Retina/Optic Nerve.- Chapter 1: United States.- Chapter 2: Belarus.- Chapter 3: Caribbean/Latin America.- Chapter 4: China.- Chapter 5: Great Britain.- Chapter 6: Indonesia.- Chapter 7: Japan.- Chapter 9: Turkey.- Section 1, Part 2: Anterior Segment.- Chapter 10: United States.- Chapter 11: Canada.- Chapter 12: China.- Chapter 13: France.- Chapter 14: Spain.- Section 2: Active, Non-recruiting Studies.- Section 2, Part 1: Retina/Optic Nerve.- Chapter 15: United States.- Chapter 16: No Location.- Section 2, Part 2: Anterior Segment.- Chapter 17: United States.- Chapter 18: Germany.- Chapter 19: Denmark.- Chapter 20: France.- Chapter 21: Spain.- Section 3: Completed Studies.- Section 3, Part 1: Retina/Optic Nerve.- Chapter 22: United States.- Chapter 23: Brazil.- Chapter 24: Turkey.- Section 3, Part 2: Anterior Segment.- Chapter 25: United States.- Chapter 26: Belarus.- Chapter 27: Iran.- Chapter 28: Korea.- Chapter 29: Spain.- Section 4: Unknown Status.- Chapter 30: Belgium.- Chapter 31: Brazil.- Chapter 32: China.- Chapter 33: Egypt.- Chapter 34: India.- Chapter 35: Jordan.- Chapter 36: Korea.- Chapter 37: Lebanon.- Chapter 38: Malaysia.- Chapter 39: Poland.- Chapter 40: Spain.- Chapter 41: Taiwan.- Chapter 42: Thailand.- Section 5: Withdrawn Studies.- Chapter 43: United States.- Chapter 44: China.- Section 6: Terminated Studies.- Chapter 45: United States.- Chapter 46: Iran.- Section 7: Suspended Studies.- Chapter 47: Singapore.- Section 8: Analysis.- Chapter 48: Analysis of studies.- Chapter 49: Comments.